HCPCS Code J2182: Injection, Mepolizumab, 1 mg

Learn about the HCPCS code J2182 for injection, mepolizumab, 1 mg, through this short guide.

## **What is HCPCS code J2182?** The HCPCS code J2182 is for the subcutaneous injection of mepolizumab, specifically a 1 mg dose. This is commonly known as a mepolizumab injection or by its brand name, Nucala. The purpose of this drug is to control certain types of allergic, inflammatory, and chronic respiratory conditions, such as eosinophilic granulomatosis with polyangiitis, eosinophilic airway inflammation, hypereosinophilic syndrome, severe asthma, and eosinophilic asthma. Mepolizumab works by reducing the number of eosinophils in the patient’s blood. By lowering eosinophil levels, it can reduce the frequency of asthma exacerbations and other respiratory complications, making it easier for patients to breathe. Controlled clinical trials have shown that patients receiving mepolizumab experience significantly fewer exacerbations compared to those given placebo, and both adults and children aged 12 and older demonstrate a similar pharmacodynamic response. To be eligible for this injection, the patient must have severe asthma not controlled successfully by basic or usual treatments, including systemic or inhaled corticosteroids. They should also have chronic respiratory issues, frequent asthma attacks requiring corticosteroids to manage, and blood test results confirming high levels of eosinophils in the bloodstream. In terms of dosing, adults and children 12 years and older may take a total of 100 mg over several weeks of treatment. Children aged 6–11 years can only take up to 40 mg, and use in children younger than 6 years is not recommended because safety and efficacy have not been established. Patients who are on systemic corticosteroid therapy may be transitioned to mepolizumab, but corticosteroids should be tapered gradually to avoid systemic withdrawal symptoms. Mepolizumab is not a diagnostic injection and is not meant to treat acute bronchospasm or status asthmaticus. Its role is in long-term disease management rather than immediate relief. The most common adverse reactions to mepolizumab include headache, injection site reactions, fatigue, back pain, and eczema. Other common adverse reactions may involve mild respiratory infections or musculoskeletal pain. Rarely, patients may experience hypersensitivity reactions, such as angioedema, bronchospasm, or urticaria, which can occur within hours to days of administration.

## **Documentation requirements for J2182** As with any procedure, especially those involving the injection of drugs to treat patients, thorough documentation is essential before filing a claim that includes HCPCS code J2182. The following details should be clearly recorded: - The full name of the personnel who administered the injection, along with their credentials - The name and address of the facility where the injection was administered - The full name of the patient - The age of the patient (noting whether they are adult or pediatric patients) - The exact dates and times of the drug administration by injection - Patient records confirming a diagnosis such as eosinophilic granulomatosis with polyangiitis, eosinophilic airway inflammation, hypereosinophilic syndrome, severe asthma, or eosinophilic asthma - Blood test results showing elevated eosinophil levels and information about the patient’s respiratory condition - The exact dosage given throughout treatment, documented for both adult and pediatric patients Additional considerations for pediatric patients must also be included. Adult and pediatric patients aged 12 years and older may receive up to 100 mg of mepolizumab during treatment, while pediatric patients aged 6 to 11 years should not exceed 40 mg. Pediatric patients aged younger than 6 years should not be treated, as safety and efficacy have not been established. Controlled clinical trials demonstrated that patients receiving placebo experienced significantly more exacerbations than those treated with mepolizumab, with a comparable pharmacodynamic response observed in adults and pediatric patients aged 12 and above.

## **Billing requirements for J2182** Besides the documentation requirements above, please note the following billing requirements for this HCPCS code: - They must reflect the dosage given throughout the treatment. - Use either of two modifiers: JW if there's unused medication in a vial (wastage), or JZ if there's no unused medication. Also, since this injection is administered subcutaneously, please use the CPT code 96372. Do note that the American Medical Association has recognized certain monoclonal antibody agents (such as this medicine) and other biologic response modifiers as eligible for the CPT code 96401, which is a chemotherapy administration code and is meant to designate Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic. If, by any chance, you're filing for that CPT code, please include the necessary documentation related to the patient's cancer and chemotherapy treatment.

## **Other similar codes** - J2175 - Injection, meperidine HCl, per 100 mg - J2185 - Injection, meropenem, 100 mg - J2186 - Injection, meropenem, vaborbactam, 10 mg/10 mg, (20 mg) - J2212 - Injection, methylnaltrexone, 0.1 mg - J2248 - Injection, micafungin sodium, 1 mg

Frequently asked questions

The HCPCS code for mepolizumab is J2182, which covers the injection of 1 mg of the drug.

J2182 is the HCPCS code for subcutaneous injection of mepolizumab, used to treat severe eosinophilic asthma and related conditions.

Mepolizumab injection helps reduce eosinophil levels in the blood, lowering the frequency of asthma attacks and improving breathing in patients with severe eosinophilic respiratory conditions.